Search results
Results from the WOW.Com Content Network
Protease inhibitors were the second class of antiretroviral drugs developed. The first members of this class, saquinavir , ritonavir , and indinavir , were approved in late 1995–1996. Within 2 years, annual deaths from AIDS in the United States fell from over 50,000 to approximately 18,000 [ 5 ] Prior to this the annual death rate had been ...
Pages in category "Protease inhibitors" The following 27 pages are in this category, out of 27 total. This list may not reflect recent changes. ...
The U.S. Food and Drug Administration (FDA) notified healthcare professionals of updates to the prescribing information concerning interactions between protease inhibitors and certain statin drugs. Protease inhibitors and statins taken together may increase the blood levels of statins and increase the risk for muscle injury (myopathy).
Statine is a gamma amino acid that occurs twice in the sequence of pepstatin, a protease inhibitor that is active against pepsin and other acid proteases. [1] It is thought to be responsible for the inhibitory activity of pepstatin because it mimics the tetrahedral transition state of peptide catalysis.
Thymidine analogue inhibitor Efavirenz: HIV Mylan: NNRTI 1998 Elvitegravir: HIV Gilead Sciences Integrase inhibitor 2012 (Fixed-dose combo Stribild) 2014 (single pill) 2015 ; Emtricitabine: HIV Gilead Sciences NRTI 2003 Enfuvirtide: HIV Entry inhibitor 2003 Ensitrelvir: COVID-19: Shionogi: 3C-like protease inhibitor Entecavir: HIV NRTI 2005
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Pepstatin A is well known to be an inhibitor of aspartic proteases such as pepsin, cathepsins D and E. Except for its role as a protease inhibitor, however, the pharmacological action of pepstatin A upon cells remain unclear. Pepstatin A suppresses receptor activator of NF-κB ligand (RANKL)–induced osteoclast differentiation.
List of sulfonamides; Author of The Demon Under the Microscope, a history of the discovery of the sulfa drugs; A History of the Fight Against Tuberculosis in Canada (Chemotherapy) Presentation speech, Nobel Prize in Physiology and Medicine, 1939; The History of WW II Medicine "Five Medical Miracles of the Sulfa Drugs".